Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aortic endografts (EVAR/TEVAR) cases in Connecticut: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (139 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 223 | 46% |
| 2020 | 1 | 158 | 50% |
| 2021 | 0 | 149 | 53% |
| 2022 | 0 | 126 | 54% |
| 2023 | 0 | 143 | 57% |
| 2024 | 1 | 160 | 59% |
| 2025 from claims | – | 133 107–156 | 63% |
| 2026 forecast | – | 141 111–178 | 62% |
| 2027 forecast | – | 144 107–191 | 63% |
| 2028 forecast | – | 147 104–203 | 64% |
| 2029 forecast | – | 150 102–214 | 65% |
| 2030 forecast | – | 152 100–226 | 65% |
Endovascular abdominal and thoracic aortic repair. Professional codes (what the surgeon bills): CPT 34701, 34702, 34703, 34704, 34705, 34706, 33880, 33881; the hospital bills MS-DRG 268, 269, 213, 209.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Connecticut; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 7 | 818−5.7%/yr | −5.7%/yr | 0.5 | 0% | 860 in 2030+0.8%/yr |
| Pennsylvania | 1 | 705−5.5%/yr | −5.5%/yr | 0.5 | 0% | 710 in 2030+0.1%/yr |
| New Jersey | 3 | 400−7.7%/yr | −7.7%/yr | 0.4 | 0% | 360 in 2030−1.6%/yr |
| Massachusetts | 1 | 350−5.5%/yr | −5.5%/yr | 0.4 | 0% | 390 in 2030+1.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 39 | 2,246−8.9%/yr | −8.9%/yr | 6.42.0× | 100% | 2,440 in 2030+1.4%/yr |
| Dialysis access | 14 | 1,941−9.9%/yr | −9.9%/yr | 6.11.1× | 87% | 1,830 in 2030−1%/yr |
| Peripheral arterial intervention | 14 | 1,650−9%/yr | −9%/yr | 4.70.9× | 71% | 1,560 in 2030−1%/yr |
| Thrombectomy, IVC filters & venous stents | 1 | 474−5.9%/yr | −5.9%/yr | 1.41.1× | 23% | 420 in 2030−1.9%/yr |
| Carotid revascularization | 1 | 337−3.8%/yr | −3.8%/yr | 1.01.0× | 0% | 320 in 2030−1%/yr |
Aortic endografts (EVAR/TEVAR) in every state, and its device makers · Every procedure market in Connecticut · Every state · Compare with New York
Terumo leads with 32% of company spending on these surgeons in 2025, +4 pts on 2024.
In 2025, 5 companies reported engagement with Connecticut’s surgeons worth $72K in consulting, speaking, meals and travel tied to these products, about $72K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 36 clearances and approvals in the category, 2 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.